MLTO Medirect Latino Inc (CE)

MEDirect Latino Inc. (OTC:MLTO), http://www.medirectlatino.org, announced today that it will expand operations of its Medicare Reimbursement distribution model to meet increasing customer demands in Puerto Rico. Currently the Company distributes diabetic testing products to customers in the United States and in 37 of Puerto Rico's 78 municipalities. MEDirect Latino's comprehensive television advertising campaign in Puerto Rico focuses on Medicare eligible consumers, by providing direct to consumer diabetic testing supplies. Rapid growth in Puerto Rico has been achieved by distribution to those who have been underserved due to their rural location, lack of access to transportation or physical impairment, factors that restrict critical access to daily blood sugar monitoring. The expansion will include the implementing of additional infrastructure to handle added distribution capacity that the Company has experienced as a result of its comprehensive media rollout. Based upon the customer demand, which has exceeded the Company's projections, the Company is anticipating generating gross revenues of $10,190,956 within the next 12 months and EBITDA of approximately $3,000,000. MEDirect Latino is a 3-year-old, rapidly growing, federally licensed national provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider. In discussing the success of the campaign in Puerto Rico, Chief Operating Officer of MLTO, Mr. Charles W. Hansen III, stated: "The overwhelming response of the television advertising campaign which the Company is running on Telemundo, Univision and Televicentro in Puerto Rico has confirmed the proprietary algorithms that MEDirect Latino developed which pinpoints geographic concentrations of customers in need of our services. By confirming our proprietary marketing technology both in Puerto Rico and in targeted U.S. markets, the Company will now accelerate its plans to roll-out its domestic national television advertising campaign." About MEDirect Latino: MEDirect Latino (OTC:MLTO), http://www.medirectlatino.org, is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic healthcare market as a direct-to-consumer Medicare provider on an authentically national level. The Company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the US Hispanic population, noting an incidence of 120% higher than among non-Hispanic whites. Type II diabetes was also targeted because of its unique status within the Medicare reimbursement regime and because of its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These other conditions represent considerable future market potential that will allow MEDirect to efficiently scale its model by leveraging its existing client base and infrastructure. The current Hispanic market for MEDirect's products is conservatively estimated at approximately $650MM in the continental United States. The size of the opportunity is understated by such figures as an estimated 925,000 of the over 3.1 million Hispanics in the United States over 65 eligible to receive Medicare benefits are currently collecting these benefits with an estimate that over 1.4 million of those Medicare-eligible Hispanics have diabetes (implying a potential continental U.S. market for MEDirect products of approximately $1 billion). Forward-Looking Statements: Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. The Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this press release; the Company will appropriately inform the public.